List of Excipients in API bosutinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing bosutinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | BOSULIF | bosutinib | 0069-0135 | CELLULOSE, MICROCRYSTALLINE | 2030-09-26 |
| Pfizer Laboratories Div Pfizer Inc | BOSULIF | bosutinib | 0069-0135 | CROSCARMELLOSE SODIUM | 2030-09-26 |
| Pfizer Laboratories Div Pfizer Inc | BOSULIF | bosutinib | 0069-0135 | FERRIC OXIDE YELLOW | 2030-09-26 |
| Pfizer Laboratories Div Pfizer Inc | BOSULIF | bosutinib | 0069-0135 | MAGNESIUM STEARATE | 2030-09-26 |
| Pfizer Laboratories Div Pfizer Inc | BOSULIF | bosutinib | 0069-0135 | POLOXAMER 188 | 2030-09-26 |
| Pfizer Laboratories Div Pfizer Inc | BOSULIF | bosutinib | 0069-0135 | POLYETHYLENE GLYCOL 3350 | 2030-09-26 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for bosutinib
Excipient focus: CELLULOSE, MICROCRYSTALLINE
bosutinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | bosutinib | 0069-0135 |
| US Pharmaceuticals | bosutinib | 63539-117 |
| >Company | >Ingredient | >NDC |
bosutinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
bosutinib drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | bosutinib | 0069-0135 |
| US Pharmaceuticals | bosutinib | 63539-117 |
| >Company | >Ingredient | >NDC |
bosutinib drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
bosutinib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | bosutinib | 0069-0135 |
| US Pharmaceuticals | bosutinib | 63539-117 |
| >Company | >Ingredient | >NDC |
bosutinib drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
bosutinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | bosutinib | 0069-0135 |
| US Pharmaceuticals | bosutinib | 63539-117 |
| >Company | >Ingredient | >NDC |
bosutinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLOXAMER 188
bosutinib drug variants containing POLOXAMER 188
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | bosutinib | 0069-0135 |
| US Pharmaceuticals | bosutinib | 63539-117 |
| >Company | >Ingredient | >NDC |
bosutinib drug variants not containing POLOXAMER 188
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 3350
bosutinib drug variants containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | bosutinib | 0069-0135 |
| US Pharmaceuticals | bosutinib | 63539-117 |
| >Company | >Ingredient | >NDC |
bosutinib drug variants not containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
bosutinib drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | bosutinib | 0069-0135 |
| US Pharmaceuticals | bosutinib | 63539-117 |
| >Company | >Ingredient | >NDC |
bosutinib drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE K25
bosutinib drug variants containing POVIDONE K25
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | bosutinib | 0069-0135 |
| US Pharmaceuticals | bosutinib | 63539-117 |
| >Company | >Ingredient | >NDC |
bosutinib drug variants not containing POVIDONE K25
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
bosutinib drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | bosutinib | 0069-0135 |
| US Pharmaceuticals | bosutinib | 63539-117 |
| >Company | >Ingredient | >NDC |
bosutinib drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
bosutinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | bosutinib | 0069-0135 |
| US Pharmaceuticals | bosutinib | 63539-117 |
| >Company | >Ingredient | >NDC |
bosutinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
